Company research
ROCKWELL MEDICAL, INC.
CIK 1041024Updated Sep 26, 2026
SecurityRMTI · NASDAQ · equity
Name history
ROCKWELL MEDICAL TECHNOLOGIES INC · through Jun 14, 2012
RMTI price & chart
Loading TradingView…
NASDAQ:RMTI on TradingView ↗About the company
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & ProductionTM in 2024, Rockwell Medical is …
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.03, 5.03, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 57,145,000Source | 59,208,000Source | 52,173,000Source | 46,635,000Source |
| Property, Plant and Equipment, NetUSD | 4,629,000Source | 5,785,000Source | 6,402,000Source | 2,194,000Source |
| GoodwillUSD | 921,000Source | 921,000Source | 921,000Source | 921,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 9,656,000Source | 10,207,000Source | 10,759,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,711,000Source | 15,662,000Source | 8,983,000Source | 10,102,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 8,143,000Source | 8,291,000Source | 10,901,000Source | 6,259,000Source |
| Inventory, NetUSD | 3,424,000Source | 5,778,000Source | 5,871,000Source | 5,814,000Source |
| Assets, CurrentUSD | 38,163,000Source | 37,030,000Source | 28,770,000Source | 35,310,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,599,000Source | 1,359,000Source | 1,063,000Source | 1,745,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,569,000Source | 3,215,000Source | 2,713,000Source | — |
| Other Assets, NoncurrentUSD | 556,000Source | 528,000Source | 527,000Source | 523,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 20,164,000Source | 26,622,000Source | 30,882,000Source | 32,529,000Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 439,838,000Source | 430,207,000Source | 418,487,000Source | 402,701,000Source |
| Retained Earnings (Accumulated Deficit)USD | -402,992,000Source | -397,678,000Source | -397,198,000Source | -388,759,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 131,000Source | 54,000Source | -1,000Source | 163,000Source |
| Stockholders' Equity Attributable to ParentUSD | 36,981,000Source | 32,586,000Source | 21,291,000Source | 14,106,000Source |
| Liabilities and EquityUSD | 57,145,000Source | 59,208,000Source | 52,173,000Source | 46,635,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,580,000Source | 14,091,000Source | 16,637,000Source | 17,691,000Source |
| Operating Lease, Liability, CurrentUSD | 1,155,000Source | 1,566,000Source | 1,381,000Source | — |
| Accounts Payable, CurrentUSD | 1,999,000Source | 2,869,000Source | 4,516,000Source | 4,053,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,454,000Source | 1,699,000Source | 1,433,000Source | — |
| Other Liabilities, NoncurrentUSD | — | 0Source | 14,000Source | 14,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | 8,143,000Source | 8,291,000Source | 10,901,000Source | — |
| Accrued Liabilities, CurrentUSD | 4,337,000Source | 6,275,000Source | 7,149,000Source | 7,702,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 25,000,000Source | 21,600,000Source | 10,900,000Source | 21,500,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 0Source | 1,631,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 8,826,000Source | 8,472,000Source | 8,293,000Source | 7,555,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,192,000Source | 2,180,000Source | 1,444,000Source | 576,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,816,000Source | 1,292,000Source | 932,000Source | 315,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 98,000Source | -2,610,000Source | 4,642,000Source | 346,000Source |
| Increase (Decrease) in InventoriesUSD | -2,779,000Source | 332,000Source | -1,176,000Source | 2,101,000Source |
| Increase (Decrease) in Accounts PayableUSD | -870,000Source | -1,647,000Source | 463,000Source | 314,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -659,000Source | 4,202,000Source | -9,412,000Source | -17,414,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -8,544,000Source | -4,866,000Source | -3,045,000Source | -2,396,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,252,000Source | 7,348,000Source | 11,342,000Source | 16,632,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -4,951,000Source | 6,679,000Source | -1,119,000Source | -3,178,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,711,000Source | 15,662,000Source | 8,983,000Source | 10,102,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 772,000Source | 847,000Source | 1,209,000Source | 1,470,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 0Source | -5,000Source | -4,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,816,000Source | 1,292,000Source | 932,000Source | 315,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 354,000Source | 426,000Source | 1,107,000Source | 369,000Source |
| Amortization of Intangible AssetsUSD | — | — | 300,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 25,000,000Source | 21,600,000Source | 10,900,000Source | 21,500,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 267,000Source | 74,000Source | 321,000Source | 4,000Source |
| DepreciationUSD | 1,600,000Source | 1,600,000Source | 1,200,000Source | 576,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 3,000Source |
| Gain (Loss) on Disposition of AssetsUSD | -57,000Source | 0Source | -1,000Source | 3,000Source |
| Gain (Loss) on Termination of LeaseUSD | 24,000Source | — | — | — |
| General and Administrative ExpenseUSD | 14,032,000Source | 14,108,000Source | 12,142,000Source | 15,644,000Source |
| GoodwillUSD | 921,000Source | 921,000Source | 921,000Source | 921,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 1,124,000Source | 1,254,000Source | — | — |
| Inventory Write-downUSD | 178,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 211,000Source | 33,000Source |
| Net Income (Loss) Attributable to ParentUSD | -5,314,000Source | -480,000Source | -8,439,000Source | -18,679,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -5,467,000Source | -782,000Source | -8,589,000Source | — |
| Operating Lease, ExpenseUSD | 1,868,000Source | 1,608,000Source | 1,672,000Source | 2,098,000Source |
| Other Nonoperating Income (Expense)USD | -623,000Source | -1,088,000Source | -1,769,000Source | -1,899,000Source |
| Proceeds from Issuance of Common StockUSD | 7,816,000Source | 10,181,000Source | 14,861,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 69,258,000Source | 101,489,000Source | 83,612,000Source | 72,810,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | 57,563,000Source | 84,005,000Source | 74,908,000Source | 68,733,000Source |
| Operating Income (Loss)USD | -4,691,000Source | 608,000Source | -6,670,000Source | -16,780,000Source |
| Other Nonoperating Income (Expense)USD | -623,000Source | -1,088,000Source | -1,769,000Source | -1,899,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -5,314,000Source | -480,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -5,314,000Source | -480,000Source | -8,439,000Source | -18,679,000Source |
| Earnings Per Share, BasicUSD per share | -0.15Source | -0.03Source | -0.37Source | -1.89Source |
| Earnings Per Share, DilutedUSD per share | -0.15Source | -0.03Source | -0.37Source | -1.89Source |
| Total Revenue | — | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 35,974,231Source | 31,058,539Source | 23,322,915Source | 9,866,844Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 35,974,231Source | 31,058,539Source | 23,322,915Source | 9,866,844Source |
| Interest Expense (non-operating)USD | 1,124,000Source | 1,254,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 300,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 3,000Source |
| General and Administrative ExpenseUSD | 14,032,000Source | 14,108,000Source | 12,142,000Source | 15,644,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 11,695,000Source | 17,484,000Source | 8,704,000Source | 4,077,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -5,314,000Source | -480,000Source | — | — |
| Interest ExpenseUSD | — | — | 2,301,000Source | 1,936,000Source |
| Investment Income, InterestUSD | — | — | 211,000Source | 33,000Source |
| Investment Income, NetUSD | 234,000Source | 92,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -5,467,000Source | -782,000Source | -8,589,000Source | — |
| Operating Lease, ExpenseUSD | 1,868,000Source | 1,608,000Source | 1,672,000Source | 2,098,000Source |
| Research and Development ExpenseUSD | 0Source | 19,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 69,258,000Source | 101,489,000Source | 83,612,000Source | 72,810,000Source |
| Selling and Marketing ExpenseUSD | 2,354,000Source | 2,749,000Source | 2,125,000Source | 2,094,000Source |
Filing attachments
tm2514651d1_ex99-1.htm · 8-K · 2025-05-12
EX-99.1 2 tm2514651d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rockwell Medical Announces First Quarter 2025 Results Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Wixom, Michigan, May 12, 2025 - Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, …
Read attachment ↗tm259810d1_ex99-1.htm · 8-K · 2025-03-20
EX-99.1 2 tm259810d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% incr…
Read attachment ↗